IL32 and metastatic malignant neoplasm in the lymph nodes: Others have shown higher rates of IL32-immunopositivity in primary tumors derived from patients with lymph node metastasis as well as in metastatic as compared to corresponding primary tumors, regardless the location of distant metastases [48].